LAS190792

LAS190792 (also known as AZD8999) is a novel inhaled bifunctional molecule that acts as both a muscarinic receptor antagonist and a β2-adrenoceptor agonist (MABA). It is designed for the treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The drug exhibits potent antagonism at muscarinic receptors, particularly M3, and selective agonism at the β2-adrenoceptor over β1 and β3 subtypes. Preclinical studies demonstrate that LAS190792 has strong bronchodilatory effects with sustained duration of action, minimal cardiac side effects, and potential anti-inflammatory properties. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with COPD and asthma[2][5][6][7].